Full Text View
Tabular View
No Study Results Posted
Related Studies
PRIDE - Prograf Investigation of Diet and Exercise. A Pilot Trial of the Effect of Dietary and Exercise Intervention in Patients Who Have Received a Renal Transplant on Tacrolimus (Prograf®)
This study is currently recruiting participants.
Study NCT00492661   Information provided by Janssen-Cilag Pty Ltd
First Received: June 25, 2007   Last Updated: April 30, 2009   History of Changes
This Tabular View shows the required WHO registration data elements as marked by

June 25, 2007
April 30, 2009
July 2007
Proportion of patients with insulin resistance, as defined by a homeostasis model assessment (HOMA-IR) of >1 at 6 months.
Same as current
Complete list of historical versions of study NCT00492661 on ClinicalTrials.gov Archive Site
Proportion of patients with composite endpoint of impaired fasting glycaemia (IFG) /impaired glucose tolerance (IGT) /diabetes mellitus (DM) at 6 months.
Same as current
 
PRIDE - Prograf Investigation of Diet and Exercise. A Pilot Trial of the Effect of Dietary and Exercise Intervention in Patients Who Have Received a Renal Transplant on Tacrolimus (Prograf®)
A Pilot Trial of the Effect of Dietary and Exercise Intervention on Insulin Resistance and Metabolic Parameters in de Novo Renal Transplant Recipients on Prograf® (Tacrolimus)

The purpose of this trial is to investigate whether a combined dietary and exercise intervention, added to standard care, reduces the expected frequency of insulin resistance in kidney transplant recipients on tacrolimus.

This study will investigate the effect of a supervised diet and exercise program on the risk of developing diabetes and other related conditions after kidney transplantation. The exercise and diet intervention will include a 6-month program of weight lifting exercises (progressive resistance training) which will be completed three times each week and individualised dietary advice from a qualified dietician. Diabetes is very common following transplantation, developing in up to one-third of kidney transplant recipients. The development of diabetes requires treatment and places those affected at an increased risk of other complications including reduced transplant survival. This is a prospective (subjects are identified and then followed forward in time), single-arm, multicentre, interventional pilot study of the effects of a combined dietary and exercise intervention on glucose metabolism. The subject population includes kidney transplant recipients who have been assigned a tacrolimus-based immunosuppression regimen. The study will include the following evaluations of safety and tolerability; adverse events will be reported by the patient for the duration of the study, a physical examination will be completed by the investigator at each study visit, laboratory investigations and an ECG will be performed at each study visit.

Phase IV
Interventional
Prevention, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study
  • Renal Transplantation
  • Transplantation, Renal
  • Grafting, Kidney
  • Transplantation, Kidney
Drug: FK506 Prograf (tacrolimus) with diet and exercise intervention.
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
60
 
December 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Received a living-donor or dead-donor, blood type compatible kidney transplant
  • Patient has sufficiently recovered from surgery to tolerate an intensive exercise evaluation
  • Patient is 18 years or older at the time of transplantation
  • Patient has been initiated on tacrolimus (Prograf)

Exclusion Criteria:

  • No significant disease or disability that prevents taking part in a diet or exercise regime (e.g. cardiac instability, including unstable angina and/or other unstable disease, severe cognitive impairment)
  • No significant post-surgical complications that prevent participation in the exercise component of the study (e.g. wound dehiscence or infection)
  • No contraindications to maximal exercise testing or high-intensity progressive resistance training (e.g. proliferative diabetic or hypertensive retinopathy, un-repaired aneurysm, critical aortic stenosis, recurrent symptomatic hernias, New York Heart Association (NYHA) class IV congestive heart failure)
  • No mobility problems
  • Patient does not require ongoing systemic immunosuppressive therapy for an indication other than renal transplant e.g. rheumatoid arthritis, and this dose is higher than that required for their kidney disease
Both
18 Years and older
No
Contact: Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions: info1@veritasmedicine.com
Australia
 
 
NCT00492661
Executive Director, Medical & Scientific Affairs, Janssen-Cilag Pty Ltd
 
Janssen-Cilag Pty Ltd
 
Study Director: Janssen-Cilag Pty Ltd Clinical Trial Janssen-Cilag Pty Ltd
Janssen-Cilag Pty Ltd
April 2009

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.